Dermatological Complications of Diabetes Mellitus; Allergy to Insulin and Oral Agents

  • George I. VargheseEmail author
  • Maliha Mathew
  • Ellen Marmur
  • Mathew C. Varghese
Reference work entry


Diabetes mellitus is a chronic disease involved with the dysregulation of glucose metabolism through defects in insulin production and action. Diabetes has a significant impact on multiple organ systems, including the skin. Most patients will eventually develop cutaneous manifestations of the disease. Oftentimes it is the initial presenting symptom of an underlying diagnosis of diabetes. The range of cutaneous findings is broad, ranging from idiopathic inflammatory conditions, such as granuloma annulare and necrobiosis lipoidica, to metabolic derangements of the skin seen in acanthosis nigricans and acrochordans. Neuropathic and vasculopathic changes in long-standing diabetes can lead to chronic ulcerations of the skin. Even therapeutic management of diabetes can lead to unwanted cutaneous side effects. This chapter will focus on the clinical features, pathogenesis, and treatment modalities of the various dermatologic manifestations of the diabetes.


Acanthosis nigricans Acrochordons Cutaneous infection Diabetic ulcer Drug reaction Granuloma annulare Lipoatrophy Necrobiosis lipoidica diabeticorum Scleredema diabeticorum 


  1. 1.
    Perez MI, Kohn SR. Cutaneous manifestations of diabetes mellitus. J Am Acad Dermatol. 1994;30:519–31.CrossRefPubMedGoogle Scholar
  2. 2.
    Braverman IM. Skin signs of systemic disease. Philadelphia: WB Saunders; 1981. p. 654–64.Google Scholar
  3. 3.
    Reid SD, Ladizinski B, Lee K, Baibergenova A, Alavi A. Update on necrobiosis lipoidica: a review of etiology, diagnosis, and treatment options. J Am Acad Dermatol. 2013;69:783–91.CrossRefPubMedGoogle Scholar
  4. 4.
    Korber A, Dissemond J. Necrobiosis lipoidica diabeticorum. CMAJ. 2007;177:12.CrossRefGoogle Scholar
  5. 5.
    Quimby SR, Muller SA, Schroeter AL. The cutaneous immunopathology of necrobiosis lipoidica diabeticorum. Arch Dermatol. 1988;124(9):1364–71.CrossRefPubMedGoogle Scholar
  6. 6.
    Mirkamali A, Carbonnelle-Puscian A, Bagot M. Ulcerated necrobiosis lipoidica: successful treatment with topical tacrolimus and hydroxychloroquine. Ann Dermatol Venereol. 2010;137:561–2.CrossRefPubMedGoogle Scholar
  7. 7.
    Kavala M, Sudogan S, Zindanci I, Kocaturk E, Can B, Turkoglu Z, et al. Significant improvement in ulcerative necrobiosis lipoidica with hydroxychloroquine. Int J Dermatol. 2010;49:467–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Dabski K, Winkelmann RK. Generalized granuloma annulare: clinical and laboratory findings in 100 patients. J Am Acad Dermatol. 1989;20:39–47.CrossRefPubMedGoogle Scholar
  9. 9.
    Thornsberry L, English J. Etiology, diagnosis, and therapeutic management of granuloma annulare: an update. Am J Clin Dermatol. 2013;14:279–90.CrossRefPubMedGoogle Scholar
  10. 10.
    Thyresson HN, Doyle JA, Winkelmann RK. Granuloma annulare: histopathologic and direct immunofluorescence study. Acta Derm Venereol. 1980;60:261.PubMedGoogle Scholar
  11. 11.
    Lukács J, Schliemann S, Elsner P. Treatment of generalized granuloma annulare – a systematic review. J Eur Acad Dermatol Venereol. 2015;29(8):1467–80.CrossRefPubMedGoogle Scholar
  12. 12.
    Marcus DV, Mahmoud BH, Hamzavi IH. Granuloma annulare treated with rifampin, ofloxacin, and minocycline combination therapy. Arch Dermatol. 2009;145:787–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Shmer A, Bergman R, Linn S, Kantor Y, Friedman-Birnbaum R. Diabetic dermopathy and internal complications of diabetes mellitus. Int J Dermatol. 1998;37:113–5.CrossRefGoogle Scholar
  14. 14.
    Morgan AJ, Schwartz RA. Diabetic dermopathy: a subtle sign with grave implications. J Am Acad Dermatol. 2008;58(3):447–51. Epub 2007 Dec 21.CrossRefPubMedGoogle Scholar
  15. 15.
    Wigington G, Ngo B, Rendell M. Skin blood flow in diabetic dermopathy. Arch Dermatol. 2004;140:1248–50.CrossRefPubMedGoogle Scholar
  16. 16.
    Brik R, Berant M, Vardi P. The scleredema-like syndrome of insulin dependent diabetes mellitus. Diabetes Metab Rev. 1991;7(2):120–8. Review.CrossRefPubMedGoogle Scholar
  17. 17.
    Rongioletti F, Kaiser F, Cinotti E, Metze D, Battistella M, Calzavara-Pinton PG, Damevska K, Girolomoni G, André J, Perrot JL, Kempf W, Cavelier-Balloy B. Scleredema. A multicentre study of characteristics, comorbidities, course and therapy in 44 patients. J Eur Acad Dermatol Venereol. 2015;29(12):2399–404Google Scholar
  18. 18.
    Thumpimukvatana N, Wongpraparut C, Lim H. Scleredema diabeticorum successfully treated with ultraviolet A1 phototherapy. J Dermatol. 2010;37:1036–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Starkman HS, Gleason RE, Rand LI, et al. Limited joint mobility of the hands in patients with diabetes mellitus. Ann Rheum Dis. 1986;45:130–5.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Lieberman LS, Rosenbloom AC, Riley WJ, et al. Reduced skin thickness with pump administration of insulin. N Engl J Med. 1980;303:940–1.PubMedGoogle Scholar
  21. 21.
    Eaton P, Sibbitt WL, Harsh A. The effect of an aldose reductase inhibiting agent on limited joint mobility in diabetic patients. JAMA. 1985;253:1437–40.CrossRefPubMedGoogle Scholar
  22. 22.
    Eaton RP, Sibbitt WL, Shah VO, et al. A commentary on 10 years of aldose reductase inhibition for limited joint mobility in diabetes. J Diabetes Complications. 1998;12:34–8.CrossRefPubMedGoogle Scholar
  23. 23.
    Gerrits EG, Landman GW, Nijenhuis-Rosien L, Bilo HJ. Limited joint mobility syndrome in diabetes mellitus: a minireview. World J Diabetes. 2015;6(9):1108–12.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Sabin JA. Bacterial infections in diabetes mellitus. Br J Dermatol. 1974;91:481.CrossRefGoogle Scholar
  25. 25.
    Knight L, Fletcher J. Growth of Candida albicans in saliva: stimulation by glucose associated with antibiotics, corticosteroids and diabetes mellitus. J Infect Dis. 1971;123:371–7.CrossRefPubMedGoogle Scholar
  26. 26.
    Tomford JW, Whittlesey D, Ellner JJ, Tomashefski JF. Invasive primary cutaneous phycomycosis in diabetic leg ulcers. Arch Surg. 1980;115:770–1.CrossRefPubMedGoogle Scholar
  27. 27.
    Rashid M, Bari A, Majeed S, et al. Mucormycosis: a devastating fungal infection in diabetics. J Coll Physicians Surg Pak. 2005;15:43–5.PubMedGoogle Scholar
  28. 28.
    De Locht M, Boelaert JR, Schneider YJ. Iron uptake from ferrioxamine and from ferrirhizoferrin by germinating spores of Rhizopus microsporus. Biochem Pharmacol. 1994;47:1843–50.CrossRefPubMedGoogle Scholar
  29. 29.
    Adam RD, Hunter G, DiTomasso J, Comerci Jr G. Mucormycosis: emerging prominence of cutaneous infections. Clin Infect Dis. 1994;19(1):67–76.CrossRefPubMedGoogle Scholar
  30. 30.
    Yohai RA, Bullock JD, Aziz AA, Markert RJ. Survival factors in rhino-orbital-cerebral mucormycosis. Surv Ophthalmol. 1994;39(1):3–22.CrossRefPubMedGoogle Scholar
  31. 31.
    Spanakis EK, Aperis G, Mylonakis E. New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage. Clin Infect Dis. 2006;43(8):1060–8.CrossRefPubMedGoogle Scholar
  32. 32.
    Alteras I, Saryt E. Prevalence of pathogenic fungi in the toe-webs and toe-nails of diabetic patients. Mycopathologia. 1979;67:157–9.CrossRefPubMedGoogle Scholar
  33. 33.
    Celestin R, Brown J, Kihiczak G, Schwartz RA. Erysipelas; a common potentially dangerous infection. Acta Dermatovenerol APA. 2007;16(3):123–7.Google Scholar
  34. 34.
    Calhoun JH, Mader JT. Infection in the diabetic foot. Hosp Pract. 1992;30:81–140.Google Scholar
  35. 35.
    Brook I, Frazier EH. Clinical and microbiological features of necrotizing fasciitis. J Clin Microbiol. 1995;33:2382–7.PubMedPubMedCentralGoogle Scholar
  36. 36.
    Wong CH, Chang HC, Pasupathy S, Khin LW, Tan JL, Low CO. Necrotizing fasciitis: clinical presentation, microbiology, and determinants of mortality. J Bone Joint Surg Am. 2003;85-A(8):1454–60.CrossRefPubMedGoogle Scholar
  37. 37.
    Rubin Grandis J, Branstetter 4th BF, Yu VL. The changing face of malignant (necrotising) external otitis: clinical, radiological, and anatomic correlations. Lancet Infect Dis. 2004;4(1):34–9.CrossRefPubMedGoogle Scholar
  38. 38.
    Rubin J, Yu VL. Malignant external otitis: insights into pathogenesis, clinical manifestations, diagnosis, and therapy. Am J Med. 1988;85(3):391–8.CrossRefPubMedGoogle Scholar
  39. 39.
    Barrow HN, Levenson MJ. Necrotizing malignant” external otitis caused by, Staphylococcus epidermidis. Arch Otolaryngol Head Neck Surg. 1992;118:94–6.CrossRefPubMedGoogle Scholar
  40. 40.
    Montes LF, Dobson H, Dodge BG, Knowles WR. Erythrasma and diabetes mellitus. Arch Dermatol. 1969;99:674–80.CrossRefPubMedGoogle Scholar
  41. 41.
    Basarab T, Munn SE, McGrath J, Jones RR. Bullous diabeticorum. A case report and literature review. Clin Exp Dermatol. 1995;20:218–20.CrossRefPubMedGoogle Scholar
  42. 42.
    Bernstein JE, Medenica M, Soltani K, et al. Bullous eruption of diabetes mellitus. Arch Dermatol. 1979;115:324–5.CrossRefPubMedGoogle Scholar
  43. 43.
    Gilchrest B, Rowe JW, Mihm MC. Bullous dermatosis of hemodialysis. Ann Intern Med. 1975;83:480–3.CrossRefPubMedGoogle Scholar
  44. 44.
    Glynne P, et al. Bullous dermatoses in end-stage renal failure: porphyria or pseudoporphyria? Am J Kidney Dis. 1999;34:155–60.CrossRefPubMedGoogle Scholar
  45. 45.
    Vadoud-Sayedi J, et al. Treatment of hemodialysis-associated pseudoporphyria with N-acetycysteine: report of two cases. Br J Dermatol. 2000;142:580–1.CrossRefGoogle Scholar
  46. 46.
    Hermanns-Le T, Scheen A, Pierard GE. Acanthosis nigricans associated with insulin resistance: pathophysiology and management. Am J Clin Dermatol. 2004;5:199–203.CrossRefPubMedGoogle Scholar
  47. 47.
    Veysey E, Ratnavel R. Facial acanthosis nigricans associated with obesity. Am J Clin Dermatol. 2005;30:437–9.Google Scholar
  48. 48.
    Simha V, Garg A. Phenotypic heterogeneity in body fat distribution in patients with congenital generalized lipodystrophy caused by mutations in the AGPAT2 or seipin genes. J Clin Endocrinol Metab. 2003;88:5433–7.CrossRefPubMedGoogle Scholar
  49. 49.
    Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90:1929–35.CrossRefPubMedGoogle Scholar
  50. 50.
    Cruz Jr P, Hud Jr J. Excess insulin binding to insulin-like growth factor receptors: proposed mechanism for acanthosis nigricans. J Invest Dermatol. 1992;98:82S.CrossRefPubMedGoogle Scholar
  51. 51.
    Podolsky S. Lipoatrophic diabetes and leprechaunism. In: Podolsky S, Viswanthan M, editors. The spectrum of the diabetic syndromes. New York: Raven; 1980. p. 335–52.Google Scholar
  52. 52.
    Lawrence RD. Lipodystrophy and hepatomegaly with diabetes, lipemia, and other metabolic disturbances. Lancet. 1946;250:724–31.CrossRefGoogle Scholar
  53. 53.
    Mabry CC, Hollingsworth DR, Upton CV, Corbin A. Pituitary-hypothalamic dysfunction in generalized lipodystrophy. J Pediatr. 1973;82(4):625–33.CrossRefPubMedGoogle Scholar
  54. 54.
    Oseid S, Beck-Nielsen H, Pederson O, Sovik O. Decreased binding of insulin to its receptor in patients with congential generalized lipodystrophy. N Engl J Med. 1977;296:245–8.CrossRefPubMedGoogle Scholar
  55. 55.
    Garg A. Lipodystrophies. Am J Med. 2000;108(2):143–52.CrossRefPubMedGoogle Scholar
  56. 56.
    Vantyghem MC, Vigouroux C, Magre J, et al. Late-onset lipoatrophic diabetes. Phenotypic and genotypic familial studies and effect of treatment with metformin and lispro insulin analog. Diabetes Care. 1999;22:1374.CrossRefPubMedGoogle Scholar
  57. 57.
    Oral EA, Simha V, Ruiz E, et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med. 2002;346(8):570–8.CrossRefPubMedGoogle Scholar
  58. 58.
    Hoerer E, Dreyfuss F, Herzberg M. Carotenemia, skin color and diabetes mellitus. Acta Diabetol Lat. 1975;12:202–7.CrossRefPubMedGoogle Scholar
  59. 59.
    Rapini RP, Herbert AA, Drucker C. Acquired perforating dermatosis: evidence for combined transepidermal elimination of both collagen and elastic fibers. Arch Dermatol. 1989;125:1074–8.CrossRefPubMedGoogle Scholar
  60. 60.
    Bleich HL, Boro ES. Diabetic polyneuropathy: the importance of insulin deficiency, hyperglycemia and alterations in myoinositol metabolism in its pathogenesis. N Engl J Med. 1976;295:1416–20.CrossRefGoogle Scholar
  61. 61.
    Lippman HI, Perotto A, Farrar R. The neuropathic foot of the diabetic. Bull NY Acad Med. 1976;52:1159–78.Google Scholar
  62. 62.
    Levy DM, Teenghi G, Gu XH. Immunohistochemical measurements of nerves and neuropeptides in diabetic skin: relationship to tests of neurological function. Diabetologia. 1992;35:889–97.CrossRefPubMedGoogle Scholar
  63. 63.
    Javed S, Alam U, Malik RA. Burning through the pain: treatments for diabetic neuropathy. Diabetes Obes Metab. 2015;17(12):1115–25. Epub 2015 Sep 10. Review.CrossRefPubMedGoogle Scholar
  64. 64.
    Jeffcoate WJ, Harding KG. Diabetic foot ulcers. Lancet. 2003;361(9368):1545–51.CrossRefPubMedGoogle Scholar
  65. 65.
    Ajam Z, Barton SP, Marks R. Characterization of abnormalities in the cutaneous microvasculature of diabetic subjects. Br J Dermatol. 1982;107 Suppl 22:22–3.Google Scholar
  66. 66.
    Ditzel J. Functional microangiopathy in diabetes mellitus. Diabetes. 1968;17:388–97.CrossRefPubMedGoogle Scholar
  67. 67.
    Landau J, Davis E. The small blood vessels of the conjunctiva and nailbed in diabetes mellitus. Lancet. 1960;2:731–4.CrossRefPubMedGoogle Scholar
  68. 68.
    Lithner F. Purpura, pigmentation and yellow nails of the lower extremities in diabetes. Acta Med Scand. 1976;199:202–8.Google Scholar
  69. 69.
    Namazi MR, Jorizzo JL, Fallahzadeh MK. Rubeosis faciei diabeticorum: a common, but often unnoticed, clinical manifestation of diabetes mellitus. Sci World J. 2010;10:70–1.CrossRefGoogle Scholar
  70. 70.
    Nigwekar SU, Kroshinsky D, Nazarian RM, Goverman J, Malhotra R, Jackson VA, Kamdar MM, Steele DJ, Thadhani RI. Calciphylaxis: risk factors, diagnosis, and treatment. Am J Kidney Dis. 2015;66(1):133–46.CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Cheng JB, Anderson RC, Cruz Jr PD. Stevens-Johnson syndrome associated with glipizide therapy. Dermatitis. 2006;17(1):36–8.CrossRefPubMedGoogle Scholar
  72. 72.
    Kaomongkolgit R. Oral lichenoid drug reaction associated with antihypertensive and hypoglycemic drugs. J Drugs Dermatol. 2010;9(1):73–5.PubMedGoogle Scholar
  73. 73.
    Jegasothy BV. Allergic reactions to insulin. Int J Dermatol. 1980;19:139–47.CrossRefPubMedGoogle Scholar
  74. 74.
    Grammer LC, Metzger BE, Patterson R. Cutaneous allergy to human (recombinant DNA) insulin. JAMA. 1984;251:1459–60.CrossRefPubMedGoogle Scholar
  75. 75.
    Edidin DV. Cutaneous manifestations of diabetes mellitus in children. Pediatr Dermatol. 1985;2:161–79.CrossRefPubMedGoogle Scholar
  76. 76.
    Ghosh S, McCann V, Bartle L, Collier A, Malik I. Allergy to insulin detemir. Diabet Med. 2007;24:1305–7.CrossRefPubMedGoogle Scholar
  77. 77.
    Halevy S, Feuerman EJ. Abnormal glucose tolerance associated with lichen planus. Acta Derm Venereol. 1979;59:167–70.PubMedGoogle Scholar
  78. 78.
    Albrecht M, Banoczy J, Dinya E, et al. Occurrence of oral leukoplakia and lichen planus in diabetes mellitus. J Oral Pathol. 1992;21:364–6.CrossRefGoogle Scholar
  79. 79.
    Lamey PJ, Gibson J, Barclay SC, Miller S. Grinspan’s syndrome: a drug-induced phenomenon? Oral Surg Oral Med Oral Pathol. 1990;70(2):184–5.CrossRefPubMedGoogle Scholar
  80. 80.
    Chevrant-Breton J, Simon M, Bourel M, Ferrand B. Cutaneous manifestations of idiopathic hemochromatosis. Arch Dermatol. 1977;113:161–5.CrossRefPubMedGoogle Scholar
  81. 81.
    Schunter JA, Löffler D, Wiesner T, Kovacs P, Badenhoop K, Aust G, Tönjes A, Müller P, Baber R, Simon JC, Führer D, Pfäffle RW, Thiery J, Stumvoll M, Kiess W, Kratzsch J, Körner A. A novel FoxD3 variant is associated with vitiligo and elevated thyroid auto-antibodies. J Clin Endocrinol Metab. 2015;100(10):E1335–42.CrossRefPubMedGoogle Scholar
  82. 82.
    Kahana M, Grossman E, Feinstein A, et al. Skin tags: a cutaneous marker for diabetes mellitus. Acta Derm Venereol. 1986;67:175–7.Google Scholar
  83. 83.
    Demir S, Demir Y. Acrochordon and impaired carbohydrate metabolism. Acta Diabetol. 2002;39(2):57–9.CrossRefPubMedGoogle Scholar
  84. 84.
    Rasi A, Soltani-Arabshahi R, Shahbazi N. Skin tag as a cutaneous marker for impaired carbohydrate metabolism: a case-control study. Int J Dermatol. 2007;46:1155–9.CrossRefPubMedGoogle Scholar
  85. 85.
    Akpinar F, Dervis E. Association between acrochordons and the components of metabolic syndrome. Eur J Dermatol. 2012;22(1):106–10.PubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  • George I. Varghese
    • 1
    Email author
  • Maliha Mathew
    • 2
  • Ellen Marmur
    • 3
  • Mathew C. Varghese
    • 1
  1. 1.Department of DermatologyWeill Cornell Medical CollegeNew YorkUSA
  2. 2.School of MedicineCornell UniversityNew YorkUSA
  3. 3.Department of DermatologyIcahn School of Medicine at Mount SinaiNew YorkUSA

Personalised recommendations